McKesson Reports Fiscal 2014 Second-Quarter Results

McKesson Corporation (NYSE:MCK) today reported that revenues for the second quarter ended September 30, 2013 were $33 billion, up 11% compared to $29.8 billion a year ago. On the basis of U.S. generally accepted accounting principles (“GAAP”), second-quarter earnings per diluted share was $1.74 compared to $1.67 a year ago.

Second-quarter Adjusted Earnings per diluted share from continuing operations was $2.27, up 19% compared to $1.91 a year ago.

For the first half of the fiscal year, McKesson generated cash from operations of $813 million, and ended the quarter with cash and cash equivalents of $3 billion. During the first half of the fiscal year, McKesson paid $99 million in dividends, had internal capital spending of $197 million, and spent $116 million on acquisitions.

“McKesson delivered another quarter of strong operating performance,” said John H. Hammergren, chairman and chief executive officer. “I am pleased with the excellent performance across all of our businesses for the first half of our fiscal year. Based on our performance to date and our expectations for the fiscal year, we are updating our previous outlook and now expect Adjusted Earnings per diluted share of $8.40 to $8.70 for the fiscal year ending March 31, 2014.”

Segment Results

Distribution Solutions revenues were up 11% in the second quarter, driven mainly by strong growth in U.S. pharmaceutical direct distribution and services revenues due to market growth, our mix of business and one additional sales day.

Canadian revenues, on a constant currency basis, increased 14% for the second quarter primarily due to market growth and new customer wins. Including an unfavorable currency impact of 5%, Canadian revenues increased 9% for the second quarter.

Medical-Surgical distribution and services revenues were up 68% for the second quarter driven primarily by the acquisition of PSS World Medical and market growth.

In the second quarter, Distribution Solutions GAAP operating profit was $685 million and GAAP operating margin was 2.13%. Second-quarter adjusted operating profit was $827 million and the adjusted operating margin was 2.57%.

Technology Solutions revenues were up 8% in the second quarter compared to the prior year driven primarily by acquisitions completed in the prior year. GAAP operating profit was $113 million for the second quarter and GAAP operating margin was 14.39%. Adjusted operating profit was $132 million for the second quarter and adjusted operating margin was 16.82%.

Fiscal Year 2014 Outlook

McKesson expects Adjusted Earnings per diluted share from continuing operations between $8.40 and $8.70 for the fiscal year ending March 31, 2014, which excludes the following GAAP items:
  • Amortization of acquisition-related intangible assets of 76 cents per diluted share.
  • Acquisition expenses and related adjustments of 23 cents per diluted share.
  • Litigation reserve adjustments of approximately 18 cents per diluted share.
  • LIFO inventory-related charges of 37 to 43 cents per diluted share.

Adjusted Earnings

McKesson separately reports financial results on the basis of Adjusted Earnings. Adjusted Earnings is a non-GAAP financial measure defined as GAAP income from continuing operations, excluding amortization of acquisition-related intangible assets, acquisition expenses and related adjustments, certain litigation reserve adjustments, and Last-In-First-Out (“LIFO”) inventory-related adjustments. A reconciliation of McKesson’s financial results determined in accordance with GAAP to Adjusted Earnings is provided in Schedules 2, 3 and 4 of the financial statement tables included with this release.

Risk Factors

Except for historical information contained in this press release, matters discussed may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These statements may be identified by their use of forward-looking terminology such as “believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates” or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements. It is not possible to predict or identify all such risks and uncertainties; however, the most significant of these risks and uncertainties are described in the company’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission and include, but are not limited to: material adverse resolution of pending legal proceedings; changes in the U.S. healthcare industry and regulatory environment; changes in the Canadian healthcare industry and regulatory environment; competition; substantial defaults in payment or a material reduction in purchases by, or the loss of, a large customer or group purchasing organization; the loss of government contracts as a result of compliance or funding challenges; public health issues in the U.S. or abroad; malfunction, failure or breach of sophisticated internal information systems to perform as designed; the adequacy of insurance to cover property loss or liability claims; the company’s failure to attract and retain customers for its software products and solutions due to integration and implementation challenges, or due to an inability to keep pace with technological advances; the company’s proprietary products and services may not be adequately protected, and its products and solutions may be found to infringe on the rights of others; system errors or failure of our technology products and solutions to conform to specifications; disaster or other event causing interruption of customer access to data residing in our service centers; the delay or extension of our sales or implementation cycles for external software products; changes in circumstances that could impair our goodwill or intangible assets; foreign currency fluctuations or disruptions to our foreign operations; new or revised tax legislation or challenges to our tax positions; the company’s ability to successfully identify, consummate, finance and integrate strategic acquisitions; general economic conditions, including changes in the financial markets that may affect the availability and cost of credit to the company, its customers or suppliers; and changes in accounting principles generally accepted in the United States of America. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

The company has scheduled a conference call for 8:30 AM ET. The dial-in number for individuals wishing to participate on the call is 719-234-7317. Erin Lampert, senior vice president, Investor Relations, is the leader of the call, and the password to join the call is ‘McKesson’. A replay of this conference call will be available for five calendar days. The dial-in number for individuals wishing to listen to the replay is 888-203-1112 (from the U.S. and Canada) or 719-457-0820 (from all other countries) and the pass code is 6981076. A webcast of the conference call will also be available live and archived on the company’s Investor Relations website at www.mckesson.com/investors.

Shareholders are encouraged to review SEC filings and more information about McKesson, which are located on the company’s website.

About McKesson

McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. We partner with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit http://www.mckesson.com.

Schedule 1
                           
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP
(unaudited)
(in millions, except per share amounts)
 
Quarter Ended September 30, Six Months Ended September 30,
2013 2012 Change 2013 2012 Change
 
Revenues $ 32,954 $ 29,755 11 % $ 65,162 $ 60,454 8 %
Cost of sales (1)   (30,945 )   (28,072 ) 10   (61,233 )   (57,210 ) 7
Gross profit 2,009 1,683 19 3,929 3,244 21
 
Operating expenses (1,295 ) (1,033 ) 25 (2,553 ) (2,083 ) 23
Litigation charges (2) (35 ) (44 ) (20 ) (50 ) (60 ) (17 )
Gain on business combination (3)   -     -   -   -     81   -
Total operating expenses   (1,330 )   (1,077 ) 23   (2,603 )   (2,062 ) 26
Operating income 679 606 12 1,326 1,182 12
Other income, net 9 10 (10 ) 15 18 (17 )
Interest expense   (59 )   (55 ) 7   (118 ) (111 ) 6
Income from continuing operations before income taxes 629 561 12 1,223 1,089 12
Income tax expense   (213 )   (162 ) 31   (387 )   (311 ) 24
Income from continuing operations 416 399 4 836 778 7
Income (loss) from discontinued operations, net of tax (4)   (12 )   2   -   (8 )   3   -
Net income $ 404   $ 401   1 $ 828   $ 781   6
 
Earnings (loss) per common share (5)
Diluted
Continuing operations $ 1.79 $ 1.66 8 % $ 3.60 $ 3.24 11 %
Discontinued operations   (0.05 )   0.01   -   (0.04 )   0.01   -
Total $ 1.74   $ 1.67   4 $ 3.56   $ 3.25   10
 
Basic
Continuing operations $ 1.82 $ 1.69 8 % $ 3.67 $ 3.30 11 %
Discontinued operations   (0.06 )   0.01   -   (0.04 )   0.01   -
Total $ 1.76   $ 1.70   4 $ 3.63   $ 3.31   10
 
Weighted average common shares
Diluted 233 240 (3 ) % 232 240 (3 ) %
Basic 229 236 (3 ) 228 236 (3 )
(1)  

Cost of sales for the second quarter and first six months of fiscal years 2014 and 2013 includes charges in our Distribution Solutions segment related to our last-in-first-out (“LIFO”) method of accounting for inventories of $44 million and $3 million. Cost of sales for the first six months of fiscal year 2014 includes the receipt of $7 million and for the second quarter and first six months of fiscal year 2013 the receipt of $19 million in our Distribution Solutions segment representing our share of settlements of antitrust class action lawsuits brought against drug manufacturers.
 
(2) Represent charges for the Average Wholesale Price ("AWP") litigation.
 
(3) For the first six months of fiscal year 2013, operating expenses include an $81 million pre-tax ($51 million after-tax) gain on business combination related to the acquisition of the remaining 50% ownership interest in our corporate headquarters building.
 
(4) Represents our International Technology and Hospital Automation businesses in our Technology Solutions segment and a small business in our Distribution Solutions segment.
 
(5) Certain computations may reflect rounding adjustments.
 

Schedule 2A
                                 
McKESSON CORPORATION
RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)
(unaudited)
(in millions, except per share amounts)
 
Change
Quarter Ended September 30, 2013 Vs. Prior Quarter

As Reported(GAAP)
   

Amortizationof Acquisition-RelatedIntangibles
   

AcquisitionExpenses andRelatedAdjustments
   

LitigationReserveAdjustments
   

LIFO-RelatedAdjustments
   

AdjustedEarnings(Non-GAAP)

AsReported(GAAP)
   

AdjustedEarnings(Non-GAAP)
 
 
Revenues $ 32,954 $ - $ - $ - $ - $ 32,954 11 % 11 %
 
Gross profit $ 2,009 $ 5 $ - $ - $ 44 $ 2,058 19 22
Operating expenses (1,330 ) 65 13 35 - (1,217 ) 23 23
Other income, net 9 - - - - 9 (10 ) (10 )
Interest expense   (59 )       -         -         -         -         (59 ) 7 7
Income from continuing operations before income taxes 629 70 13 35 44 791 12 20
Income tax expense   (213 )       (25 )       (5 )       (2 )       (17 )       (262 ) 31 32
Income from continuing operations $ 416       $ 45       $ 8       $ 33       $ 27       $ 529   4 15
 

Diluted earnings per common share from continuing operations (2)
$ 1.79       $ 0.19       $ 0.03       $ 0.14       $ 0.12       $ 2.27   8 % 19 %
Diluted weighted average common shares   233         233         233         233         233         233   (3 ) % (3 ) %
 
 
Quarter Ended September 30, 2012

As Reported(GAAP)
   

Amortizationof Acquisition-RelatedIntangibles
   

AcquisitionExpenses andRelatedAdjustments
   

LitigationReserveAdjustments
   

LIFO-RelatedAdjustments
   

AdjustedEarnings(Non-GAAP)
 
Revenues $ 29,755

 
$ - $ - $ - $ - $ 29,755
 
Gross profit (1) $ 1,683

 
$ 3 $ - $ - $ 3 $ 1,689
Operating expenses (1,077 ) 44 2 44 - (987 )
Other income, net 10 - - - - 10
Interest expense   (55 )       -         -         -         -         (55 )
Income from continuing operations before income taxes 561 47 2 44 3 657
Income tax expense   (162 )       (18 )       -         (17 )       (1 )       (198 )
Income from continuing operations $ 399       $ 29       $ 2       $ 27       $ 2       $ 459  
 

Diluted earnings per common share from continuing operations (2)
$ 1.66       $ 0.12       $ 0.01       $ 0.11       $ 0.01       $ 1.91  
Diluted weighted average common shares   240         240         240         240         240         240  
(1)   For the second quarter of fiscal year 2013, gross profit includes the receipt of $19 million in our Distribution Solutions segment representing our share of settlements of antitrust class action lawsuits brought against drug manufacturers.
 
(2) Certain computations may reflect rounding adjustments.

Adjusted Earnings (Non-GAAP) Financial Information
 
Adjusted Earnings represents income from continuing operations, excluding the effects of the following items from the Company’s GAAP financial results, including the related income tax effects:
 

Amortization of acquisition-related intangibles - Amortization expense of acquired intangible assets purchased in connection with acquisitions by the Company.
 

Acquisition expenses and related adjustments - Transaction and integration expenses that are directly related to acquisitions by the Company. Examples include transaction closing costs, professional service fees, restructuring or severance charges, retention payments, employee relocation expenses, facility or other exit-related expenses, recoveries of acquisition-related expenses or post-closing expenses, bridge loan fees, and gains or losses on business combinations.
 

Litigation reserve adjustments - Adjustments to the Company’s reserves, including accrued interest, for estimated probable losses for its Average Wholesale Price and Securities Litigation matters, as such terms were defined in the Company’s Annual Reports on Form 10-K for the fiscal years ended March 31, 2013 and 2009.
 

LIFO-related adjustments - Last-In-First-Out ("LIFO") inventory-related adjustments.
 
Income taxes on Adjusted Earnings are calculated in accordance with Accounting Standards Codification 740, “Income Taxes,” which is the same accounting principle used by the Company when presenting its GAAP financial results.
 
The Company believes the presentation of non-GAAP measures such as Adjusted Earnings provides useful supplemental information to investors with regard to its core operating performance, as well as assists with the comparison of its past financial performance to the Company’s future financial results. Moreover, the Company believes that the presentation of Adjusted Earnings assists investors’ ability to compare its financial results to those of other companies in the same industry. However, the Company's Adjusted Earnings measure may be defined and calculated differently by other companies in the same industry.
 
The Company internally uses non-GAAP financial measures such as Adjusted Earnings in connection with its own financial planning and reporting processes. Specifically, Adjusted Earnings serves as one of the measures management utilizes when allocating resources, deploying capital and assessing business performance and employee incentive compensation. Nonetheless, non-GAAP financial results and related measures disclosed by the Company should not be considered a substitute for, nor superior to, financial results and measures as determined or calculated in accordance with GAAP.
 

Schedule 2B
                                 
McKESSON CORPORATION
RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)
(unaudited)
(in millions, except per share amounts)
 
Change
Six Months Ended September 30, 2013 Vs. Prior Period

As Reported(GAAP)
   

Amortizationof Acquisition-RelatedIntangibles
   

AcquisitionExpenses andRelatedAdjustments
   

LitigationReserveAdjustments
   

LIFO-RelatedAdjustments
   

AdjustedEarnings(Non-GAAP)

AsReported(GAAP)
   

AdjustedEarnings(Non-GAAP)
 
 
Revenues $ 65,162 $ - $ - $ - $ - $ 65,162 8 % 8 %
 
Gross profit (1) $ 3,929 $ 11 $ - $ - $ 44 $ 3,984 21 22
Operating expenses (2,603 ) 130 26 50 - (2,397 ) 26 20
Other income, net 15 - - - - 15 (17 ) (17 )
Interest expense   (118 )       -         -         -         -         (118 ) 6 6
Income from continuing operations before income taxes 1,223 141 26 50 44 1,484 12 27
Income tax expense   (387 )       (52 )       (10 )       (8 )       (17 )       (474 ) 24 39
Income from continuing operations $ 836       $ 89       $ 16       $ 42       $ 27       $ 1,010   7 22
 

Diluted earnings per common share from continuing operations (3)
$ 3.60       $ 0.38       $ 0.07       $ 0.18       $ 0.12       $ 4.35   11 % 26 %
Diluted weighted average common shares   232         232         232         232         232         232   (3 ) % (3 ) %
 
 
Six Months Ended September 30, 2012

As Reported(GAAP)
   

Amortizationof Acquisition-RelatedIntangibles
   

AcquisitionExpenses andRelatedAdjustments
   

LitigationReserveAdjustments
   

LIFO-RelatedAdjustments
   

AdjustedEarnings(Non-GAAP)
 
Revenues $ 60,454

 
$ - $ - $ - $ - $ 60,454
 
Gross profit (1) $ 3,244

 
$ 6 $ - $ - $ 3 $ 3,253
Operating expenses (2) (2,062 ) 89 (77 ) 60 - (1,990 )
Other income, net 18 - - - - 18
Interest expense   (111 )       -         -         -         -         (111 )
Income from continuing operations before income taxes 1,089 95 (77 ) 60 3 1,170
Income tax expense   (311 )       (35 )       29         (23 )       (1 )       (341 )
Income from continuing operations $ 778       $ 60       $ (48 )     $ 37       $ 2       $ 829  
 

Diluted earnings per common share from continuing operations (3)
$ 3.24       $ 0.25       $ (0.20 )     $ 0.15       $ 0.01       $ 3.45  
Diluted weighted average common shares   240         240         240         240         240         240  
(1)   For the first six months of fiscal years 2014 and 2013, gross profit includes the receipt of $7 million and $19 million in our Distribution Solutions segment representing our share of settlements of antitrust class action lawsuits brought against drug manufacturers.
 
(2) For the first six months of fiscal year 2013, operating expenses, as reported under GAAP, include an $81 million pre-tax ($51 million after-tax) gain on business combination related to the acquisition of the remaining 50% ownership interest in our corporate headquarters building.
 
(3) Certain computations may reflect rounding adjustments.
 

Schedule 3A
                       
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP)
(unaudited)
(in millions)
 
 
Quarter Ended September 30, 2013 Quarter Ended September 30, 2012 Change

As Reported(GAAP)
    Adjustments    

AdjustedEarnings(Non-GAAP)

As Reported(GAAP)
   

Adjustments
   

AdjustedEarnings(Non-GAAP)

AsReported(GAAP)

AdjustedEarnings(Non-GAAP)
REVENUES
Distribution Solutions
Direct distribution & services $ 23,729 $ - $ 23,729 $ 20,938 $ - $ 20,938 13 % 13 %
Sales to customers' warehouses   4,340         -       4,340     4,806         -       4,806   (10 ) (10 )

Total U.S. pharmaceutical distribution & services
28,069 - 28,069 25,744 - 25,744 9 9
Canada pharmaceutical distribution & services 2,633 - 2,633 2,409 - 2,409 9 9
Medical-Surgical distribution & services   1,467         -       1,467     873         -       873   68 68
Total Distribution Solutions   32,169         -       32,169     29,026         -       29,026   11 11
 
Technology Solutions
Services 656 - 656 585 - 585 12 12
Software 108 - 108 119 - 119 (9 ) (9 )
Hardware   21         -       21     25         -       25   (16 ) (16 )
Total Technology Solutions   785         -       785     729         -       729   8 8
Revenues $ 32,954       $ -     $ 32,954   $ 29,755       $ -     $ 29,755   11 11
 
GROSS PROFIT
Distribution Solutions (1) $ 1,623 $ 45 $ 1,668 $ 1,339 $ 4 $ 1,343 21 24
Technology Solutions   386         4       390     344         2       346   12 13
Gross profit $ 2,009       $ 49     $ 2,058   $ 1,683       $ 6     $ 1,689   19 22
 
OPERATING EXPENSES
Distribution Solutions (2) $ (944 ) $ 97 $ (847 ) $ (724 ) $ 77 $ (647 ) 30 31
Technology Solutions (273 ) 15 (258 ) (254 ) 13 (241 ) 7 7
Corporate   (113 )       1       (112 )   (99 )       -       (99 ) 14 13
Operating expenses $ (1,330 )     $ 113     $ (1,217 ) $ (1,077 )     $ 90     $ (987 ) 23 23
 
OTHER INCOME, NET
Distribution Solutions $ 6 $ - $ 6 $ 6 $ - $ 6 - -
Technology Solutions - - - 2 - 2 - -
Corporate   3         -       3     2         -       2   50 50
Other income, net $ 9       $ -     $ 9   $ 10       $ -     $ 10   (10 ) (10 )
 
OPERATING PROFIT
Distribution Solutions (1) (2) $ 685 $ 142 $ 827 $ 621 $ 81 $ 702 10 18
Technology Solutions   113         19       132     92         15       107   23 23
Operating profit 798 161 959 713 96 809 12 19
Corporate   (110 )       1       (109 )   (97 )       -       (97 ) 13 12

Income from continuing operations before interest expense and income taxes
$ 688       $ 162     $ 850   $ 616       $ 96     $ 712   12 19
 
STATISTICS
Operating profit as a % of revenues
Distribution Solutions (1) (2) 2.13 % 2.57 % 2.14 % 2.42 % (1 ) bp 15 bp
Technology Solutions 14.39 16.82 12.62 14.68 177 214
(1)  

For the second quarters of fiscal years 2014 and 2013, results, as reported under GAAP, include LIFO charges of $44 million and $3 million. For the second quarter of fiscal year 2013, results include the receipt of $19 million in our Distribution Solutions segment representing our share of settlements of antitrust class action lawsuits brought against drug manufacturers.
 
(2) For the second quarters of fiscal years 2014 and 2013, results, as reported under GAAP, include AWP litigation charges of $35 million and $44 million.
 

Schedule 3B
                       
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP)
(unaudited)
(in millions)
 
 
Six Months Ended September 30, 2013 Six Months Ended September 30, 2012 Change

As Reported(GAAP)
    Adjustments    

AdjustedEarnings(Non-GAAP)

As Reported(GAAP)
    Adjustments    

AdjustedEarnings(Non-GAAP)

As Reported(GAAP)

AdjustedEarnings(Non-GAAP)
REVENUES
Distribution Solutions
Direct distribution & services $ 46,761 $ - $ 46,761 $ 42,239 $ - $ 42,239 11 % 11 %
Sales to customers' warehouses   8,788         -       8,788     10,153         -         10,153   (13 ) (13 )

Total U.S. pharmaceutical distribution & services
55,549 - 55,549 52,392 - 52,392 6 6
Canada pharmaceutical distribution & services 5,199 - 5,199 4,926 - 4,926 6 6
Medical-Surgical distribution & services   2,824         -       2,824     1,668         -         1,668   69 69
Total Distribution Solutions   63,572         -       63,572     58,986         -         58,986   8 8
 
Technology Solutions
Services 1,317 - 1,317 1,179 - 1,179 12 12
Software 231 - 231 237 - 237 (3 ) (3 )
Hardware   42         -       42     52         -         52   (19 ) (19 )
Total Technology Solutions   1,590         -       1,590     1,468         -         1,468   8 8
Revenues $ 65,162       $ -     $ 65,162   $ 60,454       $ -       $ 60,454   8 8
 
GROSS PROFIT
Distribution Solutions (1) $ 3,143 $ 45 $ 3,188 $ 2,554 $ 5 $ 2,559 23 25
Technology Solutions   786         10       796     690         4         694   14 15
Gross profit $ 3,929       $ 55     $ 3,984   $ 3,244       $ 9       $ 3,253   21 22
 
OPERATING EXPENSES
Distribution Solutions (2) $ (1,849 ) $ 178 $ (1,671 ) $ (1,443 ) $ 129 $ (1,314 ) 28 27
Technology Solutions (554 ) 27 (527 ) (511 ) 24 (487 ) 8 8
Corporate (3)   (200 )       1       (199 )   (108 )       (81 )       (189 ) 85 5
Operating expenses $ (2,603 )     $ 206     $ (2,397 ) $ (2,062 )     $ 72       $ (1,990 ) 26 20
 
OTHER INCOME, NET
Distribution Solutions $ 10 $ - $ 10 $ 10 $ - $ 10 - -
Technology Solutions - - - 3 - 3 - -
Corporate   5         -       5     5         -         5   - -
Other income, net $ 15       $ -     $ 15   $ 18       $ -       $ 18   (17 ) (17 )
 
OPERATING PROFIT
Distribution Solutions (1) (2) $ 1,304 $ 223 $ 1,527 $ 1,121 $ 134 $ 1,255 16 22
Technology Solutions   232         37       269     182         28         210   27 28
Operating profit 1,536 260 1,796 1,303 162 1,465 18 23
Corporate   (195 )       1       (194 )   (103 )       (81 )       (184 ) 89 5

Income from continuing operations before interest expense and income taxes
$ 1,341       $ 261     $ 1,602   $ 1,200       $ 81       $ 1,281   12 25
 
STATISTICS
Operating profit as a % of revenues
Distribution Solutions (1) (2) 2.05 % 2.40 % 1.90 % 2.13 % 15 bp 27 bp
Technology Solutions 14.59 16.92 12.40 14.31 219 261
(1)  

For the first six months of fiscal years 2014 and 2013, results, as reported under GAAP, include LIFO charges of $44 million and $3 million. For the first six months of fiscal years 2014 and 2013, results include the receipt of $7 million and $19 million representing our share of settlements of antitrust class action lawsuits brought against drug manufacturers.
 
(2) For the first six months of fiscal years 2014 and 2013, results, as reported under GAAP, include AWP litigation charges of $50 million and $60 million.
 
(3) For the first six months of fiscal year 2013, operating expenses, as reported under GAAP, include an $81 million pre-tax gain on business combination related to the acquisition of the remaining 50% ownership interest in our corporate headquarters building.
 

Schedule 4A
                                   
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) - BY ADJUSTMENT TYPE
(unaudited)
(in millions)
 
 
Quarter Ended September 30, 2013 Quarter Ended September 30, 2012

DistributionSolutions
   

TechnologySolutions
   

Corporate& InterestExpense
    Total

DistributionSolutions
   

TechnologySolutions
   

Corporate& InterestExpense
    Total

As Reported (GAAP):
Revenues $ 32,169 $ 785 $ - $ 32,954 $ 29,026 $ 729 $ - $ 29,755
 
Gross profit (1) $ 1,623 $ 386 $ - $ 2,009 $ 1,339 $ 344 $ - $ 1,683
Operating expenses (944 ) (273 ) (113 ) (1,330 ) (724 ) (254 ) (99 ) (1,077 )
Other income, net   6         -         3         9     6         2         2         10  

Income from continuing operations before interest expense and income taxes
685 113 (110 ) 688 621 92 (97 ) 616
Interest expense   -         -         (59 )       (59 )   -         -         (55 )       (55 )
Income from continuing operations before income taxes $ 685       $ 113       $ (169 )     $ 629   $ 621       $ 92       $ (152 )     $ (561 )
 
 

Pre-Tax Adjustments:
Gross profit $ 1 $ 4 $ - $ 5 $ 1 $ 2 $ - $ 3
Operating expenses   52         13         -         65     31         13         -         44  
Amortization of acquisition-related intangibles 53 17 - 70 32 15 - 47
 

Operating expenses - Acquisition expenses and related adjustments
10 2 1 13 2 - - 2
 
Operating expenses - Litigation reserve adjustments 35 - - 35 44 - - 44
 
Gross profit - LIFO-related adjustments 44 - - 44 3 - - 3
                                       
Total pre-tax adjustments $ 142       $ 19       $ 1       $ 162   $ 81       $ 15       $ -       $ 96  
 
 

Adjusted Earnings (Non-GAAP):
Revenues $ 32,169 $ 785 $ - $ 32,954 $ 29,026 $ 729 $ - $ 29,755
 
Gross profit (1) $ 1,668 $ 390 $ - $ 2,058 $ 1,343 $ 346 $ - $ 1,689
Operating expenses (847 ) (258 ) (112 ) (1,217 ) (647 ) (241 ) (99 ) (987 )
Other income, net   6         -         3         9     6         2         2         10  

Income from continuing operations before interest expense and income taxes
827 132 (109 ) 850 702 107 (97 ) 712
Interest expense   -         -         (59 )       (59 )   -         -         (55 )       (55 )
Income from continuing operations before income taxes $ 827       $ 132       $ (168 )     $ 791   $ 702       $ 107       $ (152 )     $ 657  
(1)   For the second quarter of fiscal year 2013, gross profit includes the receipt of $19 million in our Distribution Solutions segment representing our share of settlements of antitrust class action lawsuits brought against drug manufacturers.
 

Schedule 4B
                                   
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) - BY ADJUSTMENT TYPE
(unaudited)
(in millions)
 
 
Six Months Ended September 30, 2013 Six Months Ended September 30, 2012

DistributionSolutions
   

TechnologySolutions
   

Corporate& InterestExpense
    Total

DistributionSolutions
   

TechnologySolutions
   

Corporate& InterestExpense
    Total

As Reported (GAAP):
Revenues $ 63,572 $ 1,590 $ - $ 65,162 $ 58,986 $ 1,468 $ - $ 60,454
 
Gross profit (1) $ 3,143 $ 786 $ - $ 3,929 $ 2,554 $ 690 $ - $ 3,244
Operating expenses (2) (1,849 ) (554 ) (200 ) (2,603 ) (1,443 ) (511 ) (108 ) (2,062 )
Other income, net   10         -         5         15     10         3         5         18  

Income from continuing operations before interest expense and income taxes
1,304 232 (195 ) 1,341 1,121 182 (103 ) 1,200
Interest expense   -         -         (118 )       (118 )   -         -         (111 )       (111 )
Income from continuing operations before income taxes $ 1,304       $ 232       $ (313 )     $ 1,223   $ 1,121       $ 182       $ (214 )     $ 1,089  
 
 

Pre-Tax Adjustments:
Gross profit $ 1 $ 10 $ - $ 11 $ 2 $ 4 $ - $ 6
Operating expenses   106         24         -         130     66         23         -         89  
Amortization of acquisition-related intangibles 107 34 - 141 68 27 - 95
 

Operating expenses - Acquisition expenses and related adjustments
22 3 1 26 3 1 (81 ) (77 )
 
Operating expenses - Litigation reserve adjustments 50 - - 50 60 - - 60
 
Gross profit - LIFO-related adjustments 44 - - 44 3 - - 3
                                       
Total pre-tax adjustments $ 223       $ 37       $ 1       $ 261   $ 134       $ 28       $ (81 )     $ 81  
 
 

Adjusted Earnings (Non-GAAP):
Revenues $ 63,572 $ 1,590 $ - $ 65,162 $ 58,986 $ 1,468 $ - $ 60,454
 
Gross profit (1) $ 3,188 $ 796 $ - $ 3,984 $ 2,559 $ 694 $ - $ 3,253
Operating expenses (1,671 ) (527 ) (199 ) (2,397 ) (1,314 ) (487 ) (189 ) (1,990 )
Other income, net   10         -         5         15     10         3         5         18  

Income from continuing operations before interest expense and income taxes
1,527 269 (194 ) 1,602 1,255 210 (184 ) 1,281
Interest expense   -         -         (118 )       (118 )   -         -         (111 )       (111 )
Income from continuing operations before income taxes $ 1,527       $ 269       $ (312 )     $ 1,484   $ 1,255       $ 210       $ (295 )     $ 1,170  
(1)   For the first six months of fiscal years 2014 and 2013, gross profit includes the receipt of $7 million and $19 million in our Distribution Solutions segment representing our share of settlements of antitrust class action lawsuits brought against drug manufacturers.
 
(2) For the first six months of fiscal year 2013, operating expenses include an $81 million pre-tax gain on business combination related to the acquisition of the remaining 50% ownership interest in our corporate headquarters building.
 

Schedule 5
           
McKESSON CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions)
 
September 30, March 31,
2013 2013
 
ASSETS
Current Assets
Cash and cash equivalents $ 2,960 $ 2,456
Receivables, net 10,321 9,975
Inventories, net 10,484 10,335
Prepaid expenses and other   780   404
Total Current Assets 24,545 23,170
Property, Plant and Equipment, Net 1,348 1,321
Goodwill 6,323 6,405
Intangible Assets, Net 2,150 2,270
Other Assets   1,581   1,620
Total Assets $ 35,947 $ 34,786
 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Drafts and accounts payable $ 16,435 $ 16,108
Deferred revenue 1,056 1,359
Deferred tax liabilities 1,529 1,626
Current portion of long-term debt 353 352
Other accrued liabilities   2,006   1,912
Total Current Liabilities 21,379 21,357
Long-Term Debt 4,521 4,521
Other Noncurrent Liabilities 2,058 1,838
Stockholders' Equity   7,989   7,070
Total Liabilities and Stockholders' Equity $ 35,947 $ 34,786
 

Schedule 6
         
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in millions)
 

Six Months Ended September 30,
2013 2012
 
 
OPERATING ACTIVITIES
Net income $ 828 $ 781
Adjustments to reconcile to net cash provided by operating activities:
Depreciation and amortization 316 252
Deferred taxes 152 398
Share-based compensation expense 73 82
Gain on business combination - (81 )
Other non-cash items 62 21
Changes in operating assets and liabilities, net of acquisitions:
Receivables (390 ) 211
Inventories (235 ) 19
Drafts and accounts payable 347 (624 )
Deferred revenue (211 ) 178
Taxes 6 (118 )
Litigation charges 50 60
Litigation settlement payments (20 ) (438 )
Other   (165 )   (282 )
Net cash provided by operating activities   813     459  
 
INVESTING ACTIVITIES
Property acquisitions (131 ) (83 )
Capitalized software expenditures (66 ) (75 )
Acquisitions, less cash and cash equivalents acquired (116 ) (251 )
Other   39     58  
Net cash used in investing activities   (274 )   (351 )
 
FINANCING ACTIVITIES
Proceeds from short-term borrowings 150 1,125
Repayments of short-term borrowings (150 ) (1,525 )
Common stock transactions:
Issuances 119 80
Share repurchases, including shares surrendered for tax withholding (128 ) (53 )
Dividends paid (99 ) (100 )
Other   71     40  
Net cash used in financing activities   (37 )   (433 )
Effect of exchange rate changes on cash and cash equivalents   2     7  
Net increase (decrease) in cash and cash equivalents 504 (318 )
Cash and cash equivalents at beginning of period   2,456     3,149  
Cash and cash equivalents at end of period $ 2,960   $ 2,831  

Copyright Business Wire 2010

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX